Literature DB >> 4564869

Lactulose: a review of its therapeutic and pharmacological properties with particular reference to ammonia metabolism and its mode of action of portal systemic encephalopathy.

G S Avery, E F Davies, R N Brogden.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1972        PMID： 4564869     DOI： 10.2165/00003495-197204010-00003

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


× No keyword cloud information.
  41 in total

1.  [The Lactobacillus bifidus factor].

Authors:  F PETUELY
Journal:  Dtsch Med Wochenschr       Date:  1957-11-15       Impact factor: 0.628

2.  A controlled clinical trial of lactulose in hepatic encephalopathy.

Authors:  F Simmons; H Goldstein; J D Boyle
Journal:  Gastroenterology       Date:  1970-12       Impact factor: 22.682

3.  Treatment of chronic portal-systemic encephalopathy with lactulose. Report of six patients and review of the literature.

Authors:  J Bircher; U P Haemmerli; G Scollo-Lavizzari; K Hoffmann
Journal:  Am J Med       Date:  1971-08       Impact factor: 4.965

4.  Brain energy metabolism in hepatic coma.

Authors:  A T Maiolo; G B Porro; C Galli; M Sessa; E E Polli
Journal:  Exp Biol Med       Date:  1971       Impact factor: 2.691

5.  [Use of lactulose in chronic constipation. (Preliminary report)].

Authors:  H Partilla
Journal:  Wien Med Wochenschr       Date:  1969-07-26

6.  Encephalopathy after portacaval shunting managed with lactulose.

Authors:  H Brown; C Trey; W V McDermott
Journal:  Am J Surg       Date:  1970-02       Impact factor: 2.565

7.  Lactulose: an ideal laxative for children.

Authors:  R T Bush
Journal:  N Z Med J       Date:  1970-06

8.  Organic anions in fecal contents.

Authors:  J S Fordtran
Journal:  N Engl J Med       Date:  1971-02-11       Impact factor: 91.245

9.  Fecal acidorrhea.

Authors:  L Bustos Fernández; E Gonzalez; A Marzi; M I Ledesma de Paolo
Journal:  N Engl J Med       Date:  1971-02-11       Impact factor: 91.245

10.  [Clinical studies with the laxative Duphalac].

Authors:  C Hernández Guío; C Ruiz Alonso
Journal:  Rev Clin Esp       Date:  1967-07-31       Impact factor: 1.556
View more
  7 in total

1.  Overanticoagulation associated with combined use of lactulose and acenocoumarol or phenprocoumon.

Authors:  Loes E Visser; Fernie J A Penning-van Beest; J H P Wilson; Arnold G Vulto; A A Harrie Kasbergen; Peter A G M De Smet; Albert Hofman; Bruno H Ch Stricker
Journal:  Br J Clin Pharmacol       Date:  2004-04       Impact factor: 4.335

Review 2.  Clinical pharmacokinetics of drugs used in the treatment of gastrointestinal diseases (Part II).

Authors:  K Lauritsen; L S Laursen; J Rask-Madsen
Journal:  Clin Pharmacokinet       Date:  1990-08       Impact factor: 6.447

3.  Lactulose therapy in Shigella carrier state and acute dysentery.

Authors:  M M Levine; R B Hornick
Journal:  Antimicrob Agents Chemother       Date:  1975-11       Impact factor: 5.191

Review 4.  Clinical practice: the management of hyperammonemia.

Authors:  Johannes Häberle
Journal:  Eur J Pediatr       Date:  2010-12-17       Impact factor: 3.183

5.  Faecal bacterial microbiota in patients with cirrhosis and the effect of lactulose administration.

Authors:  Aditya Narayan Sarangi; Amit Goel; Ankur Singh; Avani Sasi; Rakesh Aggarwal
Journal:  BMC Gastroenterol       Date:  2017-11-28       Impact factor: 3.067

6.  Lactulose may reduce Clostridium difficile-related diarrhea among patients receiving antibiotics.

Authors:  Charles Maltz; Paul F Miskovitz; Kaveh Hajifathalian
Journal:  JGH Open       Date:  2020-07-09

7.  Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis.

Authors:  Junxiong Cheng; Yafang Chen; Wenfu Cao; Guoqing Zuo
Journal:  Medicine (Baltimore)       Date:  2021-12-23       Impact factor: 1.817
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.